Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2019 Dec 27:11:10801-10806.
doi: 10.2147/CMAR.S225628. eCollection 2019.

A Case with Rectal Cancer Relapses After Clinical Complete Remission Following Neoadjuvant Chemoradiotherapy

Affiliations
Case Reports

A Case with Rectal Cancer Relapses After Clinical Complete Remission Following Neoadjuvant Chemoradiotherapy

Ping-Bao Zhang et al. Cancer Manag Res. .

Abstract

Despite advancements in diagnosis and therapy, relapse of rectal cancer after clinical complete remission (cCR) remains a frequent event. The key factors influencing the treatment strategy for the management of patients achieving cCR following neoadjuvant chemoradiotherapy (Neo-CRT) remain to be identified. We present the case of a 64-year-old man with rectal cancer. The patient was initially admitted to the hospital in September 2011 with a 3-month history of change in his stools. Following his re-hospitalization in November 2011, a biopsy specimen of the neoplasm suggested the presence of rectal adenocarcinoma; laboratory investigations also revealed elevated levels of carcinoembryonic antigens (CEA; carbohydrate antigen 199) in the serum. Subsequently, the patient received Neo-CRT, as well as symptomatic and supportive treatment. The level of serum CEA returned to normal, without signs of swollen lymph nodes in the pelvic cavity. The patient was diagnosed with rectal cancer based on the elevated level of serum CEA, colonoscopy, and contrast-enhanced magnetic resonance imaging. He relapsed 4 months after cCR following Neo-CRT and underwent laparoscopic Miles' surgery in April 2013. The relapse may have been mainly attributed to residual tumor cells. This case report and literature review may contribute to the clinical recognition of treatment for patients with rectal cancer achieving cCR following Neo-CRT.

Keywords: Neo-CRT; cCR; clinical complete remission; neoadjuvant chemoradiotherapy; rectal cancer.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest in this work.

Figures

Figure 1
Figure 1
Results of colonoscopy. (A) Colonoscopy showed an ulcer-like neoplasm situated 6 cm from the anal margin with a little bleeding, covering half of the lumen in September 2011 (arrows). (B) The re-examination of colonoscopy showed an ulcer type neoplasm on dentate line with erosion, which was brittle and subjected to hemorrhage, covering half of the lumen in November 2011 (arrows). (C) In February 2012, the re-examination of colonoscopy, which showed a 2 × 2 cm2 ulcer on distal rectal wall (near the dentate line) with white tongue coating (arrows). (D) In August 2012, the colonoscopy showed a scar with smooth surface on distal rectal wall (near the dentate line, arrows). (E) In March 2013, the colonoscopy showed a 2 cm × 4 cm neoplasm on the dentate line with erosion, which was brittle and subjected to hemorrhage (arrows).
Figure 2
Figure 2
Microscopic findings of the rectum mass. (A) Results showed tubular adenocarcinoma (H-E, original magnification, ×100). (B) The immunoenzyme labeled Ki-67 test showed 55% of the tumor tissue was positive (IH, original magnification, ×100).
Figure 3
Figure 3
Follow-up with monitoring CEA and CA199. CEA seemed more sensitive than CA199 in this case.

References

    1. Siegel RL, Miller KD, Fedewa SA, et al. Colorectal cancer statistics, 2017. CA Cancer J Clin. 2017;67(3):177–193. doi:10.3322/caac.21395 - DOI - PubMed
    1. Pohl M, Schmiegel W. Colorectal cancer – personalized, stage-adjusted tumour therapy. Dtsch Med Wochenschr. 2013;138(36):1790–1795. doi:10.1055/s-0033-1343343 - DOI - PubMed
    1. Xiao J, Tan Y, Li W, et al. Tumor volume reduction rate is superior to RECIST for predicting the pathological response of rectal cancer treated with neoadjuvant chemoradiation: results from a prospective study. Oncol Lett. 2015;9(6):2680–2686. doi:10.3892/ol.2015.3101 - DOI - PMC - PubMed
    1. Dedemadi G, Wexner SD. Complete response after neoadjuvant therapy in rectal cancer: to operate or not to operate? Digestive Dis. 2012;30(Suppl 2):109–117. doi:10.1159/000342039 - DOI - PubMed
    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67(1):7–30. doi:10.3322/caac.21387 - DOI - PubMed

Publication types